Systemic glucocorticoid therapy: A review of its metabolic and cardiovascular adverse events

Drugs

Volumn 74, Issue 15, 2014, Pages 1731-1745

  Fardet, Laurence ^a   Fève, Bruno ^b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOIDS;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INCIDENCE; LIPODYSTROPHY; METABOLIC DISORDER; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SCREENING; SYSTEMIC THERAPY; WEIGHT GAIN; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; HUMANS; METABOLIC DISEASES;

CARDIOVASCULAR DISEASES; GLUCOCORTICOIDS; HUMANS; METABOLIC DISEASES;

EID: 84910155634     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0282-9     Document Type: Review

References (136)

1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011;50(11):1982-90.
2. Overman RA, Yeh J-Y, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294-8.
3. Fardet L, Petersen I, Nazareth I. Description of oral glucocorticoid prescriptions in general population. Rev Med Interne. 2011;32(10):594-9.
4. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol. 2007;157(1):142-8.
5. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006 [cited 2012 Jul 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21938845.
6. Fardet L. Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy. Rev Med Interne. 2013;34(5):303-9.
7. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metab Clin Exp. 2011;60(11):1500-10.
8. Campbell JE, Peckett AJ, D'souza AM, Hawke TJ, Riddell MC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol. 2011;300(1):C198-209.
9. Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):86-90.
10. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197(2):189-204.
11. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275(1-2):43-61.
12. Fève B, Emorine LJ, Briend-Sutren MM, Lasnier F, Strosberg AD, Pairault J. Differential regulation of beta 1- and beta 2-adrenergic receptor protein and mRNA levels by glucocorticoids during 3T3-F442A adipose differentiation. J Biol Chem. 1990;265(27):16343-9.
13. Slavin BG, Ong JM, Kern PA. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res. 1994;35(9):1535-41.
14. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology. 1999;140(7):3188-96.
15. Hauner H, Entenmann G, Wabitsch M, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest. 1989;84(5):1663-70.
16. Chanson P, Salenave S. Metabolic syndrome in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):96-101.
17. Christ-Crain M, Kola B, Lolli F, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 2008;22(6):1672-83.
18. Lee M-J, Gong D-W, Burkey BF, Fried SK. Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study. Am J Physiol Endocrinol Metab. 2011;300(3):E571-80.
19. Lundgren M, Burén J, Ruge T, Myrnäs T, Eriksson JW. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab. 2004;89(6):2989-97.
20. Rebuffé-Scrive M, Brönnegard M, Nilsson A, Eldh J, Gustafsson JA, Björntorp P. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab. 1990;71(5):1215-9.
21. Lindroos J, Husa J, Mitterer G, et al. Human but not mouse adipogenesis is critically dependent on LMO3. Cell Metab. 2013;18(1):62-74.
22. Soumano K, Desbiens S, Rabelo R, Bakopanos E, Camirand A, Silva JE. Glucocorticoids inhibit the transcriptional response of the uncoupling protein-1 gene to adrenergic stimulation in a brown adipose cell line. Mol Cell Endocrinol. 2000;165(1-2):7-15.
23. Strack AM, Sebastian RJ, Schwartz MW, Dallman MF. Glucocorticoids and insulin: reciprocal signals for energy balance. Am J Physiol. 1995;268(1 Pt 2):R142-9.
24. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol. 1996;271(2 Pt 1):E317-25.
25. Spencer SJ, Tilbrook A. The glucocorticoid contribution to obesity. Stress. 2011;14(3):233-46.
26. Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF. Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology. 2004;145(6):2633-8.
27. Dallman MF, Pecoraro NC, la Fleur SE. Chronic stress and comfort foods: self-medication and abdominal obesity. Brain Behav Immun. 2005;19(4):275-80.
28. Valassi E, Santos A, Yaneva M, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383-92.
29. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-6.
30. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007;57(4):604-9.
31. Horber FF, Zürcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr. 1986;43(5):758-69.
32. Schou AJ, Heuck C, Wolthers OD. Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound. Steroids. 2003;68(6):525-31.
33. Arena C, Morin A-S, Blanchon T, et al. Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol. 2010;163(4):832-7.
34. Fardet L, Cabane J, Kettaneh A, Lebbé C, Flahault A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford). 2007;46(7):1102-6.
35. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ. 2012;345:e4928.
36. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-24.
37. Fardet L, Antuna-Puente B, Vatier C, et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf). 2013;78(1):43-51.
38. Fardet L, Kettaneh A, Tiev K-P, et al. Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy. Eur J Intern Med. 2008;19(5):340-4.
39. Fardet L, Flahault A, Kettaneh A, Tiev KP, Tolédano C, Cabane J. Natural history of corticosteroid-induced lipodystrophy: a prospective follow-up of 37 patients. Rev Med Interne. 2007;28(12):825-31.
40. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab. 2012;97(5):1702-11.
41. Barahona M-J, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab. 2009;94(9):3365-71.
42. Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499-506.
43. Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):77-81.
44. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95(7):3309-17.
45. Vander Kooi BT, Onuma H, Oeser JK, et al. The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol. 2005;19(12):3001-22.
46. Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19(1):29-34.
47. Beaudry JL, Riddell MC. Effects of glucocorticoids and exercise on pancreatic β-cell function and diabetes development. Diabetes Metab Res Rev. 2012;28(7):560-73.
48. Gremlich S, Roduit R, Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem. 1997;272(6):3216-22.
49. Borboni P, Porzio O, Magnaterra R, et al. Quantitative analysis of pancreatic glucokinase gene expression in cultured beta cells by competitive polymerase chain reaction. Mol Cell Endocrinol. 1996;117(2):175-81.
50. Ullrich S, Berchtold S, Ranta F, et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54(4):1090-9.
51. Saad MJ, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest. 1993;92(4):2065-72.
52. Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metab Clin Exp. 1998;47(1):3-6.
53. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17(9):717-20.
54. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619-32.
55. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728-9.
56. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97-101.
57. Kim SY, Yoo C-G, Lee CT, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci. 2011;26(2):264-7.
58. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44(3):376-81.
59. Depczynski B, Daly B, Campbell LV, Chisholm DJ, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med. 2000;17(1):15-9.
60. Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol. 1985;5(3):196-202.
61. Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol. 1997;90(6):880-3.
62. Feldman-Billard S, Lissak B, Kassaei R, Benrabah R, Héron E. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology. 2005;112(3):511-5.
63. Reynolds RM, Labad J, Sears AV, et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study. Eur J Endocrinol. 2012;166(5):861-8.
64. Burt MG, Willenberg VM, Petersons CJ, Smith MD, Ahern MJ, Stranks SN. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford). 2012;51(6):1112-9.
65. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-6.
66. Andrade-Sierra J, Contreras AM, Monteon FJ, et al. Risk factors and incidence of posttransplant diabetes mellitus in Mexican kidney recipients. Arch Med Res. 2006;37(8):961-6.
67. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64(7):979-83.
68. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105(2):c54-7.
69. Bruno A, Cavallo-Perin P, Cassader M, Pagano G. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. Arch Intern Med. 1987;147(4):679-80.
70. Pagano G, Lombardi A, Ferraris GM, Imbimbo B, Cavallo Perin P. Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects. Eur J Clin Pharmacol. 1982;22(5):469-71.
71. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96(6):1789-96.
72. Yuen KCJ, McDaniel PA, Riddle MC. Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol (Oxf). 2012;77(2):224-32.
73. Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrol Dial Transplant. 2014;29(3):698-705.
74. Kasayama S, Tanaka T, Hashimoto K, Koga M, Kawase I. Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. Diabetes Care. 2002;25(12):2359-60.
75. Van Raalte DH, van Genugten RE, Linssen MML, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34(2):412-7.
76. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983;6(1):23-5.
77. Onwubalili JK, Obineche EN. High incidence of post-transplant diabetes mellitus in a single-centre study. Nephrol Dial Transplant. 1992;7(4):346-9.
78. Lemke U, Krones-Herzig A, Berriel Diaz M, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008;8(3):212-23.
79. Fain JN, Cheema P, Tichansky DS, Madan AK. Stimulation of human omental adipose tissue lipolysis by growth hormone plus dexamethasone. Mol Cell Endocrinol. 2008;295(1-2):101-5.
80. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294(5549):2166-70.
81. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA. 2004;101(18):7088-93.
82. Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2010;316(2):154-64.
83. el-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J. 1973;2(5858):85-6.
84. Jefferys DB, Lessof MH, Mattock MB. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J. 1980;56(657):491-3.
85. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53(4):528-35.
86. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metab Clin Exp. 1984;33(6):521-6.
87. Brotman DJ, Girod JP, Garcia MJ, et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab. 2005;90(6):3202-8.
88. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987;63(2-3):167-72.
89. Kuroki Y, Kaji H, Kawano S, et al. Prospective short-term effects of glucocorticoid treatment on glucose and lipid metabolism in Japanese. Intern Med. 2010;49(10):897-902.
90. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593-602.
91. Greenman Y. Management of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):91-5.
92. Pinheiro CH da J, Sousa Filho WM de, Oliveira Neto J de, et al. Exercise prevents cardiometabolic alterations induced by chronic use of glucocorticoids. Arq Bras Cardiol. 2009;93(4):400-8, 392-400.
93. Montrella-Waybill M, Clore JN, Schoolwerth AC, Watlington CO. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab. 1991;72(5):1060-6.
94. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989;62(5):375-91.
95. Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl. 1996;14(5):S37-41.
96. Fardet L, Kettaneh A, Gérol J, Tolédano C, Tiev K-P, Cabane J. Short-term effect of dietary-sodium intake on arterial blood pressure of patients treated with systemic corticosteroids: a prospective, randomised, crossover study. Rev Med Interne. 2009;30(9):741-6.
97. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens. 1989;7(7):537-49.
98. Whitworth JA, Kelly JJ. Evidence that high dose cortisol-induced Na + retention in man is not mediated by the mineralocorticoid receptor. J Endocrinol Invest. 1995;18(7):586-91.
99. Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol. 2008;19(7):1291-9.
100. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol. 2001;28(12):993-6.
101. Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol. 1992;43(5):409-13.
102. Peppa M, Krania M, Raptis SA. Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review. Integr Blood Press Control. 2011;4:7-16.
103. Ong SLH, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am. 2011;40(2):393-407, ix.
104. Sato A, Funder JW, Okubo M, Kubota E, Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens. 1995;8(8):823-8.
105. Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47(1):72-5.
106. Zacharieva S, Torbova S, Orbetzova M, et al. Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension. Methods Find Exp Clin Pharmacol. 1998;20(5):433-8.
107. Zacharieva S, Orbetzova M, Natchev E, et al. Losartan in Cushing's syndrome. Methods Find Exp Clin Pharmacol. 1998;20(2):163-8.
108. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170-5.
109. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101(8):759-67.
110. Trementino L, Arnaldi G, Appolloni G, et al. Coagulopathy in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):55-9.
111. Ren R, Oakley RH, Cruz-Topete D, Cidlowski JA. Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology. 2012;153(11):5346-60.
112. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764-70.
113. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859-65.
114. Van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016-20.
115. Varas-Lorenzo C, Rodriguez LAG, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376-83.
116. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502-17.
117. Stahn C, Löwenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;275(1-2):71-8.
118. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23-43.
119. Vayssière BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol. 1997;11(9):1245-55.
120. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol. 2001;166(3):1975-82.
121. Schäcke H, Schottelius A, Döcke W-D, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA. 2004;101(1):227-32.
122. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317-33.
123. Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol. 1995;22(9):1660-2.
124. Miner JN, Tyree C, Hu J, et al. A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol. 2003;17(1):117-27.
125. Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol. 2003;17(5):860-9.
126. Patel R, Williams-Dautovich J, Cummins CL. Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues. Mol Endocrinol. 2014;28(7):999-1011.
127. Yi C-X, Foppen E, Abplanalp W, et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes. 2012;61(2):339-45.
128. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet. 1993;342(8877):949-54.
129. Rupa V, Jacob M, Mathews MS, Seshadri MS. A prospective, randomised, placebo-controlled trial of postoperative oral steroid in allergic fungal sinusitis. Eur Arch Otorhinolaryngol. 2010;267(2):233-8.
130. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741-51.
131. Secchi A, Pastore MR, Sergi A, Pontiroli AE, Pozza G. Prednisone administration in recent onset type I diabetes. J Autoimmun. 1990;3(5):593-600.
132. Powell-Tuck J, Bown RL, Chambers TJ, Lennard-Jones JE. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion. 1981;22(5):263-70.
133. Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest. 1965;48(3):287-90.
134. Raúl Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazár-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res. 1998;29(3):259-62.
135. Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672-80.
136. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16(11):876-83.